about
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab.Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective studyLong-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature.Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.Tofacitinib for the treatment of psoriasis.Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.Brodalumab for the treatment of psoriasis.Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.Tildrakizumab for treating psoriasis.The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis.Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis.Linear psoriasis following the typical distribution of the sciatic nerve.IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients.Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome.HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.Long-term efficacy of adalimumab in generalized pustular psoriasis.Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumabEfalizumabPatients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab SuspensionEfficacy of Short-Term Cyclosporine Treatment to Control Psoriasis-Related Events during Efalizumab TherapyLong-term treatment of plaque psoriasis with efalizumab: an Italian experienceA clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumabA safety evaluation of guselkumab for the treatment of psoriasisSecukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observationPsoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumabContinuous treatment of plaque-type psoriasis with etanercept: an observational long-term experienceErythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis
P50
Q33670059-CE995A4C-81DA-4FF3-BA91-EA21A9A2079CQ35977689-8B2C1BFF-EDA9-4A4B-86B4-ACDA2FE81547Q36202783-BECE611F-82B4-4A3D-BA47-550787E5C4A7Q36755241-21067E2A-5306-4154-99F9-77CBF0C07698Q37251321-AE031D3D-6779-4027-A7BA-3218ECE96070Q38856883-783B4E35-72D9-44F8-8E27-0C3EE37F0144Q38957282-C2498C77-B1A2-4887-8098-736954FEC5DBQ38975719-1864F514-C779-485C-A56D-5AFA6CC89ECFQ38983870-A67EAF84-39AD-4B02-9C44-122E36EDE1CCQ39167757-1A6C591E-C8EB-4E00-9059-8DADD698A67BQ39218034-4179C3CB-ADB4-4C3D-AF4A-38B45640F84DQ39244594-274A1496-0310-49D0-9C5E-D575885F4B4FQ39275772-72D89904-1C37-4447-9EB8-8D33136BF559Q39869674-356D8785-0BD9-48BB-BE57-7FEEE37B33C9Q39982486-4EF1A710-9399-45DB-AD89-0D1CA77E9F53Q40201234-1E11DA6C-1FD7-4B38-BB06-6A5C8FAA0DB4Q42623928-FC1795A5-6A92-4002-99FF-A625A68C444EQ43623630-DA80EB10-982C-4E6D-ADDF-3BBF87C4C49BQ43918672-D8B4A4C9-0C39-4E51-85C5-09B3194AA883Q47230622-B4A24ED2-0FB8-455B-88EE-7AE83F3CD28DQ47291490-B1737865-E44F-4CF3-9592-1E76AE0501A5Q48060378-52951343-0578-4B64-9F44-7FFC4AEAFA72Q48092986-AD4CE2C3-0CA6-4F62-92CF-5FAA49094C75Q50545844-40EEC349-7564-4702-AD0A-7236C82C7379Q50747285-54090C08-48A2-44D3-9C2A-2C33C6B528DFQ50927361-42CC4DA6-84FB-42B3-944C-55684F21F370Q51191920-3F65184F-7273-4D00-9A6F-C9A65618ED6DQ52900365-224442CB-F659-419F-88EF-9D3DA974BDE2Q55050105-BF7737E8-BFB5-4D90-9AD6-2A61BD8321CEQ58434824-D57FFDD9-8FCE-4F7E-B09E-AFFA05A682ABQ58434864-0A309146-D9D3-4548-861C-BB141769040CQ58434874-D11DD8B5-6883-4DE0-9E8A-F9767F5F5136Q58434925-6409844D-EA3C-4B90-8439-148660164462Q58434978-C700EE17-95D1-4793-AA57-05569259EA25Q59309366-6376D9FF-E41F-40BA-8B16-C0035E8A41A9Q59309377-532B80FD-F81A-4199-80E9-3204CA19370DQ59309381-4A29E946-E549-461D-BD4D-2A6A4F57E5CAQ59309387-0FE74138-9CB8-43A1-AFD2-AE6B1407018FQ84581686-7ED8794D-403E-4F21-A998-E27E0C73E80DQ86731108-D4FA3A85-5AC8-4795-B679-62E32E528B0C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
M Talamonti
@ast
M Talamonti
@en
M Talamonti
@es
M Talamonti
@nl
type
label
M Talamonti
@ast
M Talamonti
@en
M Talamonti
@es
M Talamonti
@nl
prefLabel
M Talamonti
@ast
M Talamonti
@en
M Talamonti
@es
M Talamonti
@nl
P106
P1153
24402134700
57189196533
P31
P496
0000-0002-3070-4071